A subscription to JoVE is required to view this content. Sign in or start your free trial.
Review Article
This review focuses on current diagnostic and therapeutic innovations in glaucoma management, with emphasis on how evidence from landmark clinical trials, imaging biomarkers, artificial intelligence-assisted diagnostics, laser and surgical advances, neuroprotective research, and personalized treatment frameworks can be translated into clinical decision-making.
Glaucoma is a progressive optic neuropathy and a leading cause of irreversible blindness worldwide. Although lowering intraocular pressure (IOP) remains the only proven intervention that consistently slows disease progression, glaucomatous damage results from the interaction of mechanical, vascular, inflammatory, metabolic, and genetic mechanisms that affect retinal ganglion cell survival and optic nerve head integrity. This narrative review identified literature through searches of PubMed/MEDLINE, Web of Science, Scopus, and Google Scholar for English-language publications from January 2000 to May 2026, prioritizing landmark clinical trials, recent reviews, guidelines, and studies addressing diagnostic imaging, artificial intelligence, medical therapy, laser treatment, minimally invasive glaucoma surgery, neuroprotection, and personalized glaucoma care. Current management is shifting from a pressure-only model toward earlier detection and risk-based intervention using optical coherence tomography, optical coherence tomography angiography, automated perimetry, home monitoring, tele-ophthalmology, and artificial intelligence-assisted analytics. Therapeutic innovations include fixed-dose combinations, Rho-kinase inhibitors, sustained-release drug delivery systems, selective laser trabeculoplasty as an evidence-supported first-line option for selected patients, minimally invasive glaucoma surgery, and improved drainage implants. Emerging neuroprotective, regenerative, and gene-based strategies may eventually complement IOP reduction, but these approaches remain investigational until durable clinical efficacy is demonstrated. This review distinguishes established clinical practice from emerging evidence and future perspectives, emphasizing how biomarkers, treatment adherence, disease stage, life expectancy, socioeconomic barriers, and patient-specific risk should guide long-term management. Integrating validated technologies with equitable health-system delivery is essential to reducing preventable glaucoma-related blindness.
Glaucoma is a heterogeneous set of progressive optic neuropathies that are marked by structural damage to the optic nerve head and relative visual field loss and eventual blindness that cannot be reversed in the case of non-treatment. It is also known to be among the most common causes of irreversible visual loss globally, and it has a huge burden on public health, especially in the elderly1,2,3,4,5. The insidious nature of the initial symptoms of disease development, the underdiagnosis and inaccessibility of eye-care services in most areas, also play a great role in the presentation of the disease and poor eye conditions. The number of glaucoma patients is expected to grow steadily as global life expectancy grows, complicating the processes of screening and diagnosis early and creating a greater necessity to implement effective measures to control the disease on a long-term basis5,6,7,8,9.
Glaucoma has various clinical subtypes, with primary open-angle glaucoma, primary angle-closure glaucoma, and secondary glaucomas related to ocular or systemic conditions being the most important. Even though high intraocular pressure (IOP) is the most significant modifiable risk factor, disease development and progression are multifactorial, as they are associated with vascular dysregulation, genetic susceptibility, neuroinflammation, and biomechanical stress at the level of the lamina cribrosa2. Notably, a significant percentage of patients become exposed to glaucomatous impairment in the absence of statistically significant levels of IOP, which reinforces the complicated and poorly understood pathophysiology of the illness2,3. This changing perception has reduced glaucoma from an entirely pressure-focused disease to a more inclusive neurodegenerative disease, which needs multidimensional interventions to treat. In the last 20 years, glaucoma diagnosis and management have undergone enormous changes that have altered the face of the diagnosis and management of this disease. Structural imaging advances, including optical coherence tomography (OCT) and OCT angiography, allow the early identification of retinal nerve fiber layer thinning and microvascular damage prior to functional visual field impairment manifesting1. Simultaneous advances in functional evaluation, digitally reported perimetry, and artificial intelligence-aided image processing are improving the accuracy of diagnosis, risk classification, and prognosis. They are now actively incorporated into tele-ophthalmology technologies and models of community-based screenings, and provide potential remedies for ongoing access disparities regarding specialist care. Therapeutically, the treatment of glaucoma has now expanded beyond traditional topical hypotensive agents and filtration surgery. New classes of pharmacologic agents (Rho-kinase, sustained-release drug delivery systems, fixed-dose combinations) are focused on enhancing efficacy and addressing the long-term issue of treatment adherence8. Laser therapies are being revisited as an initial intervention, with selective laser trabeculoplasty considered in the right patients1. Surgical options in new areas have also become significant in the field of surgery, with minimally invasive glaucoma surgeries and modern drainage devices now viable, offering substantial IOP reduction and improved safety profiles compared with conventional trabeculectomy or tube shunt procedures4,5,6,7. At the same time, neuroprotection, stem-cell-based regeneration, and gene therapy studies are repositioning the therapeutic horizon by targeting retinal ganglion cell (RGC) survival and disease modification rather than pressure reduction. The increased focus on precision and personalized medicine is also transforming the treatment of glaucoma. The development of genomics, biomarkers, pharmacogenomics, and real-world evidence analytics is enabling more individualized risk prediction and treatment selection1. The combination of artificial intelligence, large-scale clinical data, and home-monitoring devices offers hope for maintaining continuous disease monitoring and adaptive therapy. These methods can be especially useful in special populations where disease control should be combined with specific safety factors in management3. Nevertheless, there are still significant problems, such as the late diagnosis, socioeconomic inequalities in access to care, the lack of medication adherence, and the lifelong treatment1,5. Moreover, a variety of emerging therapies are unaffordable or insufficiently proven to be scaled up, which means they require strong clinical support and fair health-system integration. To overcome such unmet needs, it is necessary to have an in-depth appreciation of glaucoma pathophysiology, evolving diagnostics, therapeutic innovations, and future translational trends. This review is structured to address glaucoma management as a clinically evolving field rather than as a broad thesis-style literature summary. Pathophysiology and risk factors are discussed only as the foundation for current diagnostic and therapeutic decisions. The main focus is placed on innovations that are changing clinical practice, including OCT and OCTA biomarkers, digital diagnostics, artificial intelligence-based screening and progression prediction, sustained-release pharmacotherapy, SLT, MIGS, drainage implants, neuroprotective research, and precision-based treatment planning. To improve clarity, the review separates established concepts, emerging evidence, and future perspectives, and it highlights the practical implications of each development for diagnosis, treatment selection, monitoring frequency, and long-term visual preservation.
Practical applicability and clinical-use boundaries
AI-assisted glaucoma systems should be used as clinical decision-support tools, not as substitutes for ophthalmologist-led diagnosis or treatment planning. Their use is most appropriate for population screening, image triage, risk stratification, and longitudinal monitoring when algorithms have been externally validated across different ethnicities, disease severities, imaging devices, and clinical settings. Important limitations include dataset bias, poor explainability, variable performance in high myopia or media opacity, medicolegal uncertainty, privacy concerns, and workflow-integration barriers. Therefore, AI outputs should be interpreted alongside optic nerve examination, OCT/OCTA, visual field testing, IOP profile, and patient-specific risk factors10,11,12.
Tele-ophthalmology and home monitoring may improve access for patients in remote or underserved areas. They may be especially useful for stable glaucoma, ocular hypertension, poor clinic access, or patients needing frequent IOP or visual-field surveillance. However, these models are less suitable for advanced, rapidly progressive, angle-closure, secondary, pediatric, or surgically complex glaucoma unless specialist review is readily available. Home tonometry and tablet- or virtual-reality-based perimetry should complement, rather than replace, clinic-based applanation tonometry, gonioscopy, OCT, and standard automated perimetry13,14,15.
Precision medicine in glaucoma should be framed as a risk-based clinical approach rather than only a genomic concept. Patient selection should consider disease stage, baseline and target IOP, rate of OCT or visual field progression, central corneal thickness, disc hemorrhage, myopia, vascular risk, medication tolerance, likelihood of adherence, cost, life expectancy, and access to follow-up. This approach can guide monitoring frequency, earlier use of SLT or MIGS, medication simplification, and timely escalation to trabeculectomy or drainage implants when a lower target IOP is required16.
Investigational therapies, including neuroprotective agents, stem-cell-based repair, regenerative strategies, and gene therapy, should be clearly distinguished from established care. These approaches are biologically promising but should not be presented as routine clinical alternatives to IOP lowering until durable benefit is demonstrated in adequately powered clinical trials with meaningful structural and functional endpoints. At present, they should be described as future or adjunctive strategies, whereas IOP reduction remains the only consistently proven intervention for slowing glaucoma progression17.
Access restricted. Please log in or start a trial to view this content.
The evidence in this review is interpreted at three levels. Established concepts include IOP reduction, structural and functional monitoring, target IOP selection, and risk-based escalation of therapy. Emerging evidence includes OCTA biomarkers, home monitoring, tele-ophthalmology, AI-assisted detection, sustained-release drug delivery, and earlier use of SLT and MIGS in selected patients. Future perspectives include neuroprotection, stem-cell-based repair, gene therapy, and biomarker-guided precision medicine. This distinction is important because not all innovations are ready for routine clinical use; some are already influencing patient care, whereas others require stronger validation before being incorporated into standard treatment algorithms.
Pathophysiology of Glaucoma
Glaucoma is a progressive optic neuropathy with retinal ganglion cell (RGC) loss, optic nerve head (ONH) remodeling, and visual field (VF) deterioration that is multifactorial. While elevated intraocular pressure (IOP) is the most significant modifiable risk factor, glaucomatous damage results from a combination of mechanical, vascular, inflammatory, metabolic, and genetic factors11,12,13,14,15. An increase in aqueous humor outflow resistance through the TM increases IOP and induces biomechanical stress at the lamina cribrosa and ONH. This stress can impair axonal transport, alter the architecture of the extracellular matrix, and contribute to progressive damage to RGCs11,12,13, but many patients progress despite ostensibly controlled IOP, suggesting a role for pressure-independent mechanisms. The mechanisms of aqueous humor production, conventional and uveoscleral outflow, and the pathophysiology of intraocular pressure elevation are shown in Figure 1.
Vascular dysregulation and ocular-perfusion impairment lead to chronic ischemic stress, a significant factor in the development of normal-tension glaucoma. Neuroinflammatory mechanisms involving microglia, astrocytes, and Müller cells can further exacerbate damage to the ONH by releasing cytokines and activating the complement system11,12,13,14.
Oxidative stress, mitochondrial dysfunction, excitotoxicity, and neurotrophin deficiency trigger apoptotic pathways that cause RGCs to degenerate, and these pathways are modulated by genetic factors, thereby accounting for disease heterogeneity12,13,14,15. From a clinical perspective, glaucoma is a disease of the nervous system in which high IOP acts as a risk factor in combination with other vascular, metabolic, inflammatory, and genetic factors. This expanded knowledge has encouraged the development of new imaging biomarkers, neuroprotective strategies, and personalized treatment approaches beyond just pressure reduction16,17,18,19. The major cellular and molecular mechanisms underlying retinal ganglion cell degeneration in glaucoma are shown in Figure 2.
Risk factors and progression of the disease
The development of glaucoma is affected by a multifaceted interaction among demographic, ocular, systemic, and molecular factors that predetermine the disease risk and the pace of structural and functional decline20. Even though the IOP is the most important modifiable variable, many pressure-independent variables adjust the RGCs' susceptibility and optic nerve strength. These risk domains are crucial for risk stratification, risk-specific monitoring, and timely therapeutic escalation at time21,22,23,24,25,26.
Demographic risk factors
Age
Aging is the most potent non-modifiable risk factor for glaucoma development and progression, indicating the accumulation of mitochondrial and vascular maladaptation and connective tissue remodeling in ocular structures21. Epidemiological studies show a steady rise and accelerated progress in the elderly population, constantly26.
Genetic background and ethnicity
There is also physical ethnic diversity in glaucoma prevalence and severity. People of African descent have a greater incidence of primary open-angle glaucoma and a more aggressive course, and Asian groups have more vulnerability to angle-closure pathways concerning ocular structures27,28. The role of genetic predisposition in the development of diseases is also supported by family aggregation21.
Sex
The sex differences related to glaucoma depend on the subtype. In females, 9.5% have angle-closure glaucoma due to short axial length and shallow anterior chambers. In contrast, in open-angle glaucoma, the sex association is not consistent across different populations28.
Ocular risk factors
Elevated IOP
IOP is the primary variable influencing glaucoma development and progression. Both the absolute level of IOP and daytime oscillation are associated with structural and functional loss, and the only intervention that has been consistently shown to decrease the progression of the disease is the maintenance of IOP at or below26,27,28,29,30.
Biomechanics and central corneal thickness
Central corneal thickness (CCT) has been shown to be a predictor of glaucoma on its own, and greater thickness predicts glaucoma and accelerated progression, reflecting tonometric underestimation of IOP as well as innate connective-tissue vulnerability of the ONH21.
Head morphology of the optic nerve and disc hemorrhage
There are structural indicators such as a large cup-to-disc ratio, rim atrophy, and peripapillary atrophy that are associated with susceptibility to progression. Repeat optic disc bleeding is a very sensitive predictor of the future loss of visual fields and structural atrophy23,24.
Myopia and axial length
Moderate-to-high myopia is gaining importance as a major risk factor for glaucoma due to changes in scleral biomechanics and deformation of the lamina cribrosa, as well as the complexity of diagnosis in severely myopic eyes25,26,27.
Systemic risk factors
Vascular dysregulation and ocular perfusion
Low ocular perfusion pressure, systemic hypotension, nocturnal dips in blood pressure, and vasospastic conditions are among the causes of ischemic vulnerability of the ONH, especially in normal-tension glaucoma28. In controlled IOP, chronic vascular deficiency can increase structural development24.
Cardiovascular disease and metabolic disease
There is also no uniformity in the associations between glaucoma and diabetes, hypertension, dyslipidemia, and obesity, but endothelial dysfunction, oxidative stress, and microvascular compromise could underlie neuronal vulnerability and progression in susceptible individuals21,25.
Lifestyle and environmental factors
There is also growing evidence that glaucoma risk and progression may depend on exposure to air pollution and physical inactivity, among other environmental determinants, although causal interactions require further background research25,26,27,28,29.
Biomarkers and structural predictors of progression
Imaging biomarkers
Quantitative imaging based on OCT allows detection of retinal nerve fiber layer thinning, loss of ganglion cells, and deformation of the ONH before visual field deterioration is measurable21.
Functional biomarkers
Standard automated perimetry is also critical in the management of functional deterioration, and newer modalities might make it possible to identify the neuronal dysfunction and progression earlier26.
Molecular and vascular biomarkers
Biomarkers, such as inflammatory mediators, oxidative stress biomarkers, and ocular blood-flow parameters, are also being studied (and have the potential to predict progression and therapeutic response), but are not routinely used in clinical practice21,22.
Patterns and predictors of disease progression
There are no robust patterns or predictors of disease progression, with both current and past studies indicating randomness and unpredictability of disease progression trajectories.
Patterns and predictors of disease progression
No strong patterns or predictors of disease progression have been identified, and both contemporary and historical studies suggest that progression is random and unpredictable. The process of glaucoma is nonlinear and heterogeneous. Others hold steady over the years, while others tend to deteriorate very quickly despite seemingly under-managed IOP. The determinants are repeatedly determined through longitudinal cohort and clinical trials23,24,30.
Clinical implications of stratification of risk
The current management of glaucoma focuses on multidimensional risk assessment rather than on IOP alone. Demographic, structural, functional, and systemic integration is supported by: High-risk populations, Early detection, Custom target IOP selection, Greater observation of fast progressors, and On-time therapeutic escalation. Risk-stratified management is crucial for maintaining visual status over the long term and minimizing the burden of glaucoma-related blindness worldwide21,26. Multidimensional risk factors and predictors of progression in glaucoma are shown in Table 1.
Diagnostic advances
Young and good diagnosis of glaucoma is basic to the prevention of irreparable visual blindness. Since structural and functional impairments can be present years before clinical manifestations, modern management of glaucoma increasingly relies on sensitive imaging, quantitative function, and current artificial-intelligence-supported analytics. The new diagnostic process cannot only help diagnose the disease at an earlier stage but also help predict individual risks, monitor progression objectively, and provide timely therapeutic support.
Clinical evaluation
Although technological advancement is currently progressing much faster, the most cautious clinical examination remains the backbone of glaucoma diagnosis. Applanation tonometry, in measuring IOP, serves as both the baseline and longitudinal test. Nevertheless, IOP alone does not suffice to make a diagnosis, as a significant fraction of patients experience glaucomatous damage within statistically normal pressure ranges30,31,32,33,34,35. This has led to the need for a complete clinical assessment that incorporates ONH assessment, anterior chamber angle measurement, and corneal parameters. Stereoscopic optic disc imaging, obtained with slit-lamp biomicroscopy, allows determination of typical structural alterations, such as a high cup-to-disc ratio, focal neuroretinal rim thinning, peripapillary atrophy, and optic disc hemorrhages. Gonioscopy is necessary to distinguish between open-angle and angle-closure mechanisms and to inform management actions such as laser iridotomy or angle-targeted surgical procedures. The central corneal thickness value provides background information for interpreting IOP and predicting biomechanical susceptibility. These clinical elements, combined with one another, form the basis on which high-tech diagnostic technologies are built36.
Structural imaging modalities
Optical Coherence Tomography
OCT has completely transformed the diagnosis of glaucoma, as it provides the opportunity to visualize retinal and optic nerve structures with high resolution and in quantitative terms. Technologies based on the spectroscopic domain and swept-source OCT enable accurate determination of the thickness of neuronal fiber layers of the retina and the associated ganglion cell complexes, as well as the shape of the ONH. OCT typically shows structural thinning long before visual field loss can be detected, and thus OCT remains essential for detecting the disease at an early stage37,38,39,40.
Longitudinal OCT analysis enables objective evaluation of progression using event- and trend-based algorithms. Normative database integration enhances diagnostic exclusivity, whereas more sophisticated segmentation algorithms support the detection of difficult cases such as high myopia or media clouding. New swept-source platforms have also extended imaging depth to the architecture of lamina cribrosa and peripapillary choroidal structures; new data on biomechanical and vascular roles in glaucomatous pathophysiology can be gained40.
OCT angiography
OCT angiography (OCTA) is a noninvasive imaging of the retinal and ONH microvasculature without the use of dyes. A decrease in the density of vessels in the peripapillary and macular areas has been linked to early glaucoma as well as disease progression32,35. OCTA thus provides complementary data to structural OCT, vascular compromise, which can lead to or coincide with neuronal death. Variability and motion artifact have been identified as limitations, but continued development of acquisition speed and image processing has improved clinical applicability.
Functional assessment
Normalized automated perimetry
The gold standard of determining functional visual field loss in glaucoma has been standard automated perimetry (SAP). Testing strategies in which sensitivity deficits can be measured by using threshold-based testing strategies can be used to assess disease severity. Serial perimetric testing is a key factor in determining progression using global indices and pointwise trend analysis. Still, Algorithms of perimetry, based on further refinements of their thresholding plans, have advanced test efficiency and reproducibility in monitoring glaucoma37. However, patient fatigue, learning effects, and test-retest variability restrict SAP. Even the loss of early functions can go undetected until a significant percentage of RGCs have been compromised to the point that complementary modalities are developed.
New functional techniques
Short-wavelength automated perimetry, frequency-doubling technology perimetry, and microperimetry seek to identify functional impairment earlier than conventional SAP by either identifying one of the RGC subsets or localized macular sensitivity. Comparative studies indicate that microperimetry can identify early glaucomatous non-function that is not evident on normal perimetry38. Pattern electroretinography and visual evoked potentials are electrophysiologic measures that provide objective data on RGC integrity and enhance structure-function correlation in early disease33.
Digital diagnostics and artificial intelligence
Artificial intelligence (AI) and deep learning algorithms are increasingly being applied to fundus photography, OCT, OCTA, and visual field datasets to improve glaucoma detection, risk stratification, and progression prediction. Recent studies have demonstrated high diagnostic accuracy for identifying glaucomatous optic neuropathy and estimating future disease progression, particularly when multimodal datasets are integrated31,32,33,34.
AI-assisted glaucoma systems should be used as clinical decision-support tools rather than replacements for ophthalmologists. Their most appropriate applications include screening, image triage, risk stratification, and longitudinal monitoring when externally validated across diverse populations and imaging platforms. Limitations include algorithmic bias, explainability concerns, medicolegal uncertainty, privacy issues, and workflow-integration challenges. Therefore, AI outputs should always be interpreted alongside clinical examination, OCT findings, visual-field testing, and patient-specific risk factors.
AI also has important implications for population-level glaucoma care. When combined with tele-ophthalmology and community-based imaging, AI-assisted screening may expand access in underserved regions where specialist availability is limited. However, these systems should be presented as decision-support tools rather than replacements for ophthalmologists. Before broad adoption, algorithms must be externally validated across different ethnicities, disease severities, imaging devices, and clinical settings. Additional concerns include explainability, data bias, medicolegal responsibility, privacy protection, and integration with existing clinical workflows. Therefore, the current role of AI is best described as an emerging adjunct that can strengthen screening, risk stratification, and longitudinal monitoring when used within validated clinical pathways.
Home monitoring and digital health technologies
Telemedicine in glaucoma is moving from remote consultations to telemetry monitoring of intraocular pressure (IOP), visual function, and glaucoma-related structural progression. That's clinically significant, as it only measures IOP at a single point in the office and does not reflect short-term variability, diurnal variation, or nocturnal rises associated with progression35,36,37. Home and telemetric monitoring can thus be used to detect those patients who become more decompensated despite "good" clinic IOP. Noninvasive sensors for contact lenses and implantable telemetry systems are both types of telemetric IOP monitoring. Contact lens sensors estimate changes in eye dimensions related to IOP over 24 h and can help define patterns of IOP change over the course of a day38,39,40,41. They could be helpful in patients with suspected pressure-fluctuation glaucoma, normal-tension glaucoma, a mismatch between structural/functional deterioration and clinic IOP, and unexplained glaucoma progression. They are not, however, always reproducible or absolute IOP measurements, as in Goldmann applanation tonometry, and may be influenced by corneal biomechanics, lens tolerance, ocular surface disease, and sleep disturbance. Thus, contact lens sensor data should be used as additional trend information (auxiliary data) and not as a replacement for traditional tonometry42,43,44.
Intraocular pressure can be measured directly with an implantable telemetry system consisting of microsensors surgically implanted into the eye. An implantable intraocular pressure monitoring device is inserted into the ciliary sulcus, usually at the time of cataract surgery, while the pressure sensor system is placed in the suprachoroidal space, during glaucoma surgery. They send out a wireless signal containing IOP information to an external reader; these devices could provide long-term digital monitoring away from the clinic. Initial clinical trials have demonstrated feasibility, tolerability, and long-term IOP monitoring, but current utilization is hindered by surgical invasiveness, cost, device availability, calibration issues, regulatory considerations, and the need to demonstrate that telemetry-assisted decisions lead to better visual outcomes45.
The findings of Szurman et al. are of particular interest, as the pressure monitoring system showed that a suprachoroidal sensor was safe and well tolerated for 6 months and enabled continuous IOP monitoring in glaucoma patients. This can help to make telemetry a more clinically viable tool for surgical glaucoma care and provide greater IOP surveillance in patients who need it more than others, such as those with poor pressure control45,46,47.
Englisch et al. also discussed the clinical significance of using telemetry, studying short- and long-term changes in IOP in patients with primary open-angle glaucoma following successful nonpenetrating glaucoma surgery. They note that IOP is not static after surgery, and telemetry can detect pressure patterns not captured during typical clinic visits. In clinical scenarios, it could be used to optimize target IOP, identify suboptimal pressure control at an earlier stage, and facilitate adjustments to medications or surgical escalation45,46,47,48.
Overall, the use of telemetric IOP monitoring should be introduced as an adjunct to selected patients, not as standard care. It may be most useful in normal tension glaucoma, progressive glaucoma with apparent well-controlled office IOP, advanced disease with the need for tight pressure control, postoperative monitoring, and patients with possible nocturnal or diurnal pressure spikes. Limitations include cost, access, device accuracy, patient tolerance, surgical risk associated with implantable systems, universal reimbursement, and limited evidence of telemetry's contribution to long-term visual field preservation. Therefore, the use of telemetric data, combined with OCT/OCTA, standard automated perimetry, optic nerve assessment, and clinical risk stratification, is advised45,46,47,48.
Clinical implication of diagnostic innovation
The clinical implication of modern diagnostic innovation is earlier and more individualized intervention. OCT-based retinal nerve fiber layer and macular ganglion cell analysis can detect structural injury before standard perimetry becomes abnormal, while OCTA may provide complementary information about peripapillary and macular microvascular compromise. Serial visual field testing remains essential because treatment decisions must ultimately protect functional vision. The most useful diagnostic strategy is therefore multimodal: structural imaging identifies early tissue loss, functional testing confirms visual consequences, and AI-supported longitudinal analysis may help estimate the rate of progression. This approach directly informs target IOP selection, treatment escalation, and follow-up frequency, especially in patients with advanced disease, normal-tension glaucoma, high myopia, disc hemorrhage, thin CCT, or poor adherence.
Landmark clinical trials guiding current management
Several landmark clinical trials provide the evidence base for modern glaucoma management. The Ocular Hypertension Treatment Study showed that topical IOP-lowering therapy delays or prevents conversion from ocular hypertension to POAG, while also identifying risk factors such as older age, higher baseline IOP, larger cup-to-disc ratio, abnormal visual field indices, and thinner CCT. The Early Manifest Glaucoma Trial demonstrated that early IOP reduction delays progression in newly diagnosed open-angle glaucoma, including eyes with normal-pressure ranges, supporting early treatment when the risk of progression is meaningful. The Advanced Glaucoma Intervention Study reinforced the importance of sustained IOP control after surgical intervention and helped establish the clinical principle that more advanced disease often requires lower target IOP and closer visual field monitoring. The LiGHT trial further changed treatment sequencing by showing that SLT can be offered as a safe and effective first-line option for open-angle glaucoma and ocular hypertension in selected patients, reducing medication dependence and supporting a more adherence-independent treatment pathway. Together, these studies connect risk stratification, target IOP selection, treatment timing, laser therapy, and long-term monitoring in current glaucoma care.
Evaluation of AI implementation
While significant advancements have been made in research settings, several obstacles remain to the broader adoption of AI in glaucoma care. Although there has been some great work in research settings, challenges remain that need to be addressed to make AI a more common tool in glaucoma care. Many algorithms have been developed using retrospective data from very specialized centers and may not be well suited to other contexts, such as community practice, diverse ethnic groups, highly myopic eyes, media opacities, or advanced disease42–25. Furthermore, there are significant inter-device, inter-protocol, and inter-standard variations in the techniques and protocols used for imaging acquisition and reference standards, respectively, that can reduce reproducibility between centers. Some issues that remain to be resolved include regulatory approval, medicolegal accountability, data privacy, cyber security, and integration with existing EHR systems. Moreover, many deep-learning models are “black boxes” that do not allow clinicians insight into how decisions are made and may decrease clinician trust in the product being used in the clinic46. For this reason, AI cannot be used as a standalone diagnostic tool, and further validation studies of its real-world potential should be conducted before general use is recommended.
Medical management
Medical therapy remains the cornerstone of initial glaucoma treatment and long-term disease control. The principal therapeutic objective is the reduction of IOP to a level that prevents or sufficiently slows progressive structural and functional optic nerve damage. Contemporary pharmacologic strategies increasingly emphasize individualized target IOP, sustained drug delivery, improved tolerability, and enhancement of treatment adherence. In parallel, emerging agents seek to address pathophysiologic mechanisms beyond pressure reduction, including trabecular outflow resistance, vascular dysregulation, and neuroprotection47,48,49,50. The mechanism of antiglaucoma medications is shown in Figure 3.
First-line pharmacologic agents
Topical hypotensive medications constitute the standard first-line therapy for most patients with open-angle glaucoma and ocular hypertension. Prostaglandin analogs are widely regarded as preferred initial agents because of their potent IOP-lowering efficacy, once-daily dosing, and favorable systemic safety profile42,43. These agents enhance uveoscleral outflow via extracellular matrix remodeling in the ciliary muscle, resulting in sustained pressure reduction with minimal tachyphylaxis. Common adverse effects include conjunctival hyperemia, periocular pigmentation, eyelash growth, and, less commonly, cystoid macular edema in predisposed individuals. Beta-adrenergic antagonists reduce aqueous humor production by inhibiting ciliary body secretion and remain useful when prostaglandin analogues are contraindicated or insufficient as monotherapy43. However, systemic absorption may lead to cardiopulmonary adverse effects such as bradycardia, hypotension, or bronchospasm, necessitating caution in susceptible patients. Alpha-2 adrenergic agonists provide dual mechanisms of decreased aqueous production and increased uveoscleral outflow and are commonly employed as adjunctive therapy, though allergic conjunctivitis, fatigue, and central nervous system effects may limit long-term use44. Topical carbonic anhydrase inhibitors suppress aqueous humor formation via inhibition of carbonic anhydrase within the ciliary epithelium and demonstrate good ocular tolerability, while systemic formulations may produce metabolic acidosis, paresthesia, or renal calculi44. Collectively, these established drug classes form the pharmacologic foundation of stepwise escalation based on disease severity, baseline IOP, and treatment response43.
Rho-kinase inhibitors and novel pharmacologic targets
Rho-kinase (ROCK) inhibitors represent one of the most significant recent advances in topical glaucoma pharmacotherapy. By modulating cytoskeletal dynamics within the trabecular meshwork and Schlemm’s canal, these agents enhance conventional aqueous outflow and directly target the principal site of resistance in open-angle glaucoma46. Additional biologic effects, including improved ONH perfusion, antifibrotic activity, and potential neuroprotective signaling, suggest benefits that extend beyond IOP reduction45,46. Clinical use of ROCK inhibitors is associated with moderate pressure lowering and characteristic conjunctival hyperemia, subconjunctival hemorrhage, and corneal verticillata46. Ongoing investigations are exploring nitric oxide–donating prostaglandin analogs, adenosine receptor agonists, and therapies targeting mitochondrial dysfunction or neuroinflammation, reflecting a broader shift toward disease-modifying treatment paradigms45.
Fixed-dose combination therapy
As glaucoma progresses, many patients require multiple medications to achieve the target IOP. Fixed-dose combinations integrate complementary agents within a single formulation, reducing dosing frequency, preservative exposure, and treatment complexity while improving adherence47. Common combinations pair prostaglandin analogues with beta-blockers or combine aqueous-suppressant classes such as beta-blockers and carbonic anhydrase inhibitors. Evidence demonstrates comparable or superior IOP reduction relative to separate administration, together with improved persistence of therapy47. Selection should consider contraindications, tolerability, and diurnal pressure control.
Sustained-release drug delivery systems
Poor adherence to topical therapy remains a major barrier to effective glaucoma management. Sustained-release drug delivery technologies aim to overcome this limitation by providing continuous IOP reduction independent of daily patient administration48. Approaches currently in clinical use or under investigation include intracameral biodegradable implants, punctal plugs, subconjunctival depots, and drug-eluting contact lenses. These systems may offer consistent therapeutic drug levels, reduced reliance on patient adherence, decreased preservative-related ocular surface toxicity, and extended dosing intervals of months to years48. Nevertheless, considerations regarding procedural invasiveness, cost, reversibility, and long-term safety remain important for broader clinical adoption.
Treatment adherence and real-world effectiveness
Medication adherence is a critical determinant of long-term visual outcomes in glaucoma. Nonadherence may arise from complex dosing schedules, local adverse effects, financial burden, cognitive impairment, or insufficient disease awareness49. Real-world evidence consistently demonstrates lower adherence than observed in controlled clinical trials, contributing to preventable disease progression49. Strategies to improve adherence include simplified dosing regimens, fixed-dose combinations, structured patient education, reminder systems, and digital monitoring tools integrated into follow-up care47,49. Emerging remote-monitoring technologies may further enhance treatment persistence and facilitate earlier identification of inadequate IOP control.
Individualized medical therapy and target IOP
Modern glaucoma care increasingly adopts a personalized framework in which target IOP is tailored according to baseline optic nerve damage, rate of progression, life expectancy, and overall risk profile50. Mild disease may require modest pressure reduction, whereas advanced glaucoma often necessitates aggressive lowering through multidrug therapy or early transition to laser or surgical intervention41,50. Dynamic reassessment of target IOP using longitudinal structural and functional data is essential. Failure of maximal tolerated medical therapy to prevent progression should prompt timely therapeutic escalation to preserve long-term visual function42,50. Pharmacologic therapies for glaucoma, mechanisms, dosing, and safety profile are shown in Table 2.
Laser therapies
Laser-based interventions have a significant role in the modern management of glaucoma, filling the gap between incisional surgery and pharmacologic treatment. The goals of these procedures are to lower the IOP by improving aqueous humor flow or reducing aqueous humor production, and to ensure a favorable safety profile and minimal invasiveness. The developments in laser technology, treatment procedures, and patient screening have expanded the scope of lasertherapy to an interventional step-up, rather than step-down, method of treatment in some cases51,52,53. Mechanisms and anatomical targets of laser therapy in glaucoma are shown in Figure 4.
Laser trabeculoplasty
Laser trabeculoplasty with argon laser
One of the earliest laser procedures developed to treat open-angle glaucoma is argon laser trabeculoplasty (ALT), which uses thermal energy to the trabecular meshwork to increase aqueous outflow. The biologic response encompasses localized scarring, mechanical expansion of the surrounding trabecular tissue, and cell remodeling, all of which lead to a decrease in outflow resistance. ALT has shown significant improvement in IOP, both in primary open-angle glaucoma and ocular hypertension, but especially when the medical treatment fails or is ill-tolerated54. Nonetheless, ALT is linked to post-laser inflammation, development of peripheral anterior synechiae, and decreased repeatability due to cumulative structural damage to the trabecular meshwork, contributing to a clinical transition of laser modalities to newer, safer technologies with improved repeatability54.
Selective laser trabeculoplasty
Selective laser trabeculoplasty (SLT) is a huge breakthrough in laser modalities of treating open-angle glaucoma. Selective ablation of pigmented trabecular cells, with sparing of adjacent tissue, is the SLT that induces cytokine-mediated biologic remodeling, augmenting aqueous outflow without inducing the coagulative damage of ALT51. Clinical trials show that SLT has the same IOP-reducing effect as first-line topical drugs and could be effective in first-line management for up to several years52,60. Moreover, it is safe to continue with SLT once the effects of treatment have diminished, thereby serving as a permanent, adherence-free intervention53,54,55. These benefits have led to increased adoption of SLT as a first-line therapeutic modality in appropriately selected patients, despite variability in response and progressive decline in effect, which have been identified as limitations51,52,53.
Laser peripheral iridotomy
The standard intervention for angle-closure mechanisms with laser is laser peripheral iridotomy (LPI). LPI corrects a pressure ratio between the anterior and the posterior chambers by establishing an incision on the peripheral iris, therefore, alleviating pupillary block and opening up the anterior chamber angle55. This method is quite useful in acute angle-closure crises, primary angle-closure suspects, and also in chronic angle-closure glaucoma with a component of pupillary block55. LPI is relatively safe but can be associated with transiently elevated IOP, inflammation, glare, dysphotopsia, and temporary closure of the iridotomy, necessitating retreatment55. Peripheral anterior synechiae with extensive periphery, or without a pupillary block mechanism, still could require further treatment, either medical or surgical.
Laser cyclodestructive procedures
Cyclodestructive laser treatments try to decrease the IOP by suppressing the formation of aqueous humor by partially ablating the ciliary body. Conventional continuous-wave transscleral cyclophotocoagulation has always been used in refractory or advanced glaucoma due to the risk of side effects like inflammation, hypotony, and possible myopia56,57,58. Refinements in technology, such as micropulse transscleral cyclophotocoagulation, allow laser energy to be delivered in brief pulses with breaks in between, producing limited collateral tissue damage and clinically significant decreases in IOP56,58. Direct observation and precise treatment of the ciliary processes are now possible with endoscopic cyclophotocoagulation, enhancing safety and broadening the range of indicators in the setting of end-stage disease57. Nevertheless, despite the promising results, long-term comparative rates and the best possible patient-selection criteria are still under development56,57.
New and side disjunctive laser uses
Innovation is still underway to enhance glaucoma management through laser. Currently, further development of automated delivery systems and imaging-guided titration, as well as combination approaches that combine laser therapy with minimally invasive glaucoma surgery or sustained-release pharmacologic implants, is active58,59. Research patterns of care also suggest growing interest in laser trabeculoplasty in real-world clinical practice, as clinicians have greater confidence in the safety, repeatability, and cost-effectiveness of this technique59,60. The health-economic studies also indicate that early SLT can reduce cumulative treatment and medication costs compared with long-term topical therapy, especially in health care systems where adherence issues can be troublesome60. Laser therapeutic positioning occurs primarily where contact is necessary between the therapist and the client. Clinical Use of Laser Therapy Positioning: Laser therapeutic positioning occurs primarily at the site where contact between the client and therapist is required. Laser therapy is currently a diverse and more patient-centred aspect of glaucoma treatment. The critical clinical benefits are: (1) Easy invasiveness compared to incisional surgery; (2) Less reliance on pharmacist compliance; (3) Repeatability of the procedures that are chosen, such as SLT; (4) Optimal safety and speedy recuperation.
The choice of modality must be appropriate based on the subtype of glaucoma, disease stage, angle anatomy, prior treatments, and patient-specific considerations. Notably, laser treatment must be incorporated as part of a long-term management strategy that involves further follow-up and prompt surgical intervention in case of further development of the disease51,52,53,54,55,56,57,58,59,60. A comparative summary of laser therapies in glaucoma is shown in Table 3.
Surgical innovations, neuroprotection, and disease modification in glaucoma
The practical role of MIGS should be clearly distinguished from that of trabeculectomy and tube shunt surgery. MIGS procedures are most useful in patients with mild-to-moderate open-angle glaucoma, particularly when combined with cataract surgery or when reduction of medication burden is an important goal. Their favorable safety profile allows earlier procedural intervention, but the magnitude of IOP reduction is generally lower than that achieved with trabeculectomy or glaucoma drainage devices. Therefore, MIGS should not be presented as a replacement for conventional filtration surgery in advanced or rapidly progressive glaucoma. Instead, it should be positioned within a staged surgical continuum, in which the choice of procedure depends on disease severity, target IOP, conjunctival status, lens status, adherence, life expectancy, and risk tolerance.
Contemporary filtration surgery
The historic gold standard for achieving substantial and sustained IOP reduction, especially in moderate-to-advanced glaucoma with a high risk of vision loss, is trabeculectomy. Follow-up data of long-term follow-up still show the sustained pressure reduction through adjunctive antifibrotic therapy, but the surgical failure and complications are still clinically important issues61,62. Sophisticated advances, such as adjustable suturing, improved wound construction, and controlled postoperative bleb treatment, have improved results by mitigating risks, including hypotony, cataract progression, bladder leakage, and even infection.
Glaucoma drainage devices
A different stream of filtration is provided by glaucoma drainage devices (GDDs), which channel aqueous humor via a tube to an equatorial plate reservoir. Such devices are especially useful in refractory and secondary glaucomas, or in eyes with conjunctival scarring that limits the success of trabeculectomy. Recent evidence shows that strong long-term IOP is significantly reduced with acceptable safety, even though complications such as endothelial cell loss, tube exposure, diplopia, and late encapsulation are observed63,64. More recent implant models and devices developed in the region continue to improve accessibility and intermediate effectiveness across a variety of clinical conditions65. All of these trends suggest that trabeculectomy and tube shunts are currently considered supportive, not alternative, under the individualized surgical algorithm66,67,68,69.
Minimally invasive glaucoma surgery
One of the most groundbreaking procedures in modern glaucoma treatment is known as minimally invasive glaucoma surgery (MIGS). These are ab interno, microincisional interventions that are designed to stimulate the aqueous outflow, and of course, without great tissue disturbance, postoperative morbidity, as well as minimal recovery. MIGS technology Reviews: Current MIGS technology shows a positive safety profile and increasing utilization in clinical practice, especially for mild to moderate open-angle glaucoma and when combined with cataract surgery66. Synthesis of evidence on micro-porous bypassing devices in the trabecula shows a modest yet clinically significant decrease in IOP with a lower medication burden 67, whereas new suprachoroidal microstents offer alternative outflow pathways and distinct safety profiles68. Even though MIGS, in most cases, fails to produce the same level of pressure reduction as trabeculectomy, its safety and prior applicability are redefining the progressive management of glaucoma.
Shift of pressure reduction to neuroprotection
Even with successful reduction of IOP, there are still patients who report progressive optic neuropathy, demonstrating the role of pressure-independent neurodegeneration. Conceptual and translational research focuses on the central role of mitochondrial dysfunction, oxidative stress, excitotoxicity, neuroinflammation, and impaired axonal transport in the loss of RGC70,71,72,73. The signaling deprivation of neurotrophins and abnormalities of survival cues are also contributing factors to glaucomatous degeneration and underscore the need for interventions that directly preserve neuronal tissue, in addition to minimizing IOP levels74.
New neuroprotective and regenerative therapies
Several neuroprotective measures are under research. Oxidative injury, mitochondrial instability, and apoptotic signaling are promising targets of these pharmacologic efforts, yet a consistent, large-scale clinical benefit has not been established74,75,76,77,78. Much hopeful preclinical work has been done on regenerative methods, such as stem-cell-based neuroprotection, axonal regeneration, and optic nerve repair, although all are limited in translating into clinical use78,79,80. The parallel developments in the field of gene therapy indicate the potential of permanent molecular remodeling to increase neuronal survival or aqueous outflow, which is a potential game-changer in the future of glaucoma treatment79. Neuroprotection is a major future direction in glaucoma, but its current clinical role must be interpreted cautiously. Mitochondrial dysfunction, oxidative stress, neuroinflammation, impaired axonal transport, excitotoxicity, and neurotrophin deprivation are biologically plausible targets, and several pharmacologic, cell-based, and gene-based strategies have shown promise in experimental models. However, none has yet replaced IOP lowering as the proven standard method for slowing glaucomatous progression. At present, neuroprotective approaches should be described as investigational or complementary rather than established clinical therapy. Future studies require clinically meaningful endpoints, long follow-up, objective structure-function outcomes, and identification of patients most likely to benefit from pressure-independent treatment.
The embracing of surgery and neuroprotection in disease modification
The integration of new advanced surgical techniques with neuroprotection that targets biology is the harbinger of a larger shift toward proper glaucoma disease modification. Long-lasting low-IOP success with filtration surgery, drainage implants, or MIGS can establish a therapeutic context in which neuroprotective or regenerative strategies can more efficiently maintain RGC structure and function. The future care models would thus include prior safe surgical intervention, complementary neuroprotective pharmacology, biomarker-based personalization, and, ultimately, a regenerative approach using genes or cells. Neuroprotective and Regenerative Strategies in Glaucoma are shown in Table 4.
Individual and population-based therapy of glaucoma
The modern pharmacotherapy of glaucoma is increasingly moving away from the pointless approach of standardized methods directed at the prescription of treatment and at the treatment of the singular cases, with reference to biological variability, to the disease phenotype, to response to treatment, and to the context of life. Even though the reduction of IOP remains the main therapeutic goal, the growing awareness of heterogeneous disease processes and the unequal distribution of risks among groups of people makes the use of precise therapeutic options more essential81,82. The inclusion of precision medicine in the context of special population needs is thus important for maximizing visual outcomes and fostering health equity. Personalized glaucoma care should integrate biological risk with real-world feasibility. Treatment decisions should not rely solely on a single IOP value; they should also consider disease stage, rate of structural and functional progression, age, life expectancy, CCT, disc hemorrhage, myopia, vascular risk, medication tolerance, ocular surface disease, adherence probability, cost, and access to follow-up. This approach allows clinicians to select an individualized target IOP, determine whether laser or surgery should be offered earlier, and decide how frequently the patient should be monitored. Personalized care is therefore not simply a future genomic concept; it is already a practical clinical framework for aligning disease risk, treatment intensity, patient burden, and long-term visual function.
Research foundations of precision medicine in the glaucoma field
A process that must be conducted in several steps to ensure the findings are credible and statistically significant. Precision medicine in glaucoma aims to personalize diagnosis, monitoring, and treatment through a combination of genomic data, advanced imaging, functional evaluation, and environmental risk profiling. Advances in structural imaging and biomarker discovery are making earlier biomarker identification and prediction of RGC injury progression possible83. At the same time, diagnostic and prognostic models developed using artificial intelligence are proving increasingly useful for screening, risk stratification, and clinical decision support84. Genetic findings continue to unravel the sensitivity pathways, potentially informing subsequent targeted treatment approaches, thereby underscoring the translational relevance of molecular ophthalmology to personalized treatment85,86. Besides, another critical step towards precision-guided treatment planning is the refinement of individualized determination of the target IOP, which is based on baseline structural damage, rate of progression, and other risk-specific factors common to the patient87,88.
Therapeutic personalization along the disease spectrum
Individualized glaucoma therapy is a treatment concept that extends beyond diagnosis to encompass treatment choice, sequencing, and escalation. Clinicians are paying increased attention to medication tolerance, likelihood of adherence, ocular surface health, and anticipated visual outcome relative to life expectancy when deciding on appropriate therapy89,90,91. This form of personalization fosters financial sustainability for the disease and reduces its treatment burden and adverse impacts. Epidemiologic forecasts of the population can also be used to emphasize the importance of flexible treatment approaches, because the global glaucoma burden is ever-increasing, with aging populations coupled with the enhanced ability to diagnose disease85. Therefore, it is accuracy-based management that is taking center stage in the preservation of long-term vision sustainability.
Pediatric and congenital glaucoma
This is an understanding of glaucoma in children and infants, a condition previously not observed. Congenital or developmental children with glaucoma are a unique subgroup because they have anomalies in their anatomy, progression, and the effect on sight throughout life. Modern management is placing greater emphasis on early surgical interventions, genetic assessment, and lifelong developmental visual care, rather than on persistent topical therapy92. Such considerations as mutation-specific prognosis, anatomical changes associated with growth, and multidisciplinary rehabilitation require precision that presupposes the necessity of specialized lifelong monitoring.
Glaucoma in the elderly
Older adults constitute the highest percentage of people having glaucoma, and they often appear multimorbid, polypharmacic, with both mental degradation and functional frailties. Individual management of such a population should consider the expected evolution of the disease and life expectancy, the general risks of systemic medicine, and the priorities for quality of life93. Streamlined treatment regimens, long-release drug administration, or prior surgical intervention can thus offer safer and more viable long-term measures of disease management. The quality-of-life studies also reveal that visual function, autonomy, and psychosocial factors are fundamental to the success of treatment in older adults, supporting the relevance of patient-centered decision-making90.
Glaucomas of secondary and systemic diseases
Inflammatory, corticosteroid-induced, ischemic, trauma-induced, or postoperative glaucoma have a variety of pathogeneses and different prognoses and cannot be assessed and treated similarly. Additional therapy of the underlying systemic or ocular causative agent, as well as specific IOP-reducing therapy, is all that is needed to provide effective care. Complex cases are often managed with closer attention and earlier consideration of surgery before damage to the optic nerve becomes irreversible94,95,96.
Health equity, adherence, and socioeconomic determinants
Precision medicine should also go beyond biological variation to include social determinants of health, which also play a major role in the diagnosis of glaucoma, its treatment, and long-term consequences. The lack of socioeconomic wealth and access to healthcare is consistently associated with poorer disease control and higher rates of blindness92. Cost, regimen complexity, and patient education are factors that impact medication nonadherence, a major barrier to effective management91. Some of these new interventions, such as tele-ophthalmology, mobile health technologies, and community-based screening programs, present potential solutions to enhance equal access to glaucoma care and initial diagnosis at the community level95. These structural determinants are critical to addressing scientific innovation, which can be applied to actual vision maintenance. Precision-medicine determinants and population-specific considerations in glaucoma management are shown in Table 5. The integrated model of personalized and population-specific glaucoma care is shown in Figure 5.
Special populations, health-system challenges, and unmet needs in glaucoma care
Even with significant progress in the diagnostics, pharmacotherapy, laser intervention, and surgical intervention, glaucoma is still a significant source of irreversible visual loss that bears a significant burden on the world. Results are influenced not only by the mechanisms underlying biological diseases but also by vulnerabilities and health-system constraints in the population, thereby determining the continuity of treatment and long-term visual preservation. Understanding glaucoma in the context of special populations and prevailing unmet needs is hence imperative to attain equitable and effective provision.
Pediatric glaucoma
Pediatric glaucoma is a unique clinical condition with developmental angle defects, accelerated structural degeneration, and lifelong visual impairment. In contrast to adult health, there is a prioritization of early surgical repair, the prevention of amblyopia, and long-term observation of ocular growth and refractive development. Modern series of surgeries have proven to have significant control of IOP with aqueous shunt operations, though complications and the repeated need for operations are still major concerns96. Current developments in the management of childhood glaucoma emphasize earlier, genetic, and multidisciplinary follow-up over time to maintain visual function throughout the lifespan97. The missed opportunity due to late diagnosis at critical stages of neurodevelopment might lead to permanent visual impairment; hence, pediatric glaucoma is a clinical and population-health risk factor within global blindness-prevention programs.
Glaucoma in pregnancy
Hormonal changes in glucose metabolism make the process of glaucoma management in pregnant women complicated in terms of therapeutic decisions that take into account the risk of fetal exposure to antiglaucoma medications and physiologic changes in IOP and restrictions in timing procedures. The behavior of variable disease during pregnancy has been observed to vary, requiring a risk-benefit assessment and adjustment of treatment96,97,98, which is on a case-to-case basis to harmonize maternal vision preservation with fetal safety. In the event it is possible, clinicians may prefer pre-pregnancy stabilization, reduction of medication load, and the conscious use of laser or surgery when evidently required, with close collaboration between ophthalmology and obstetric medical care.
Steroid-induced glaucoma
Steroid-induced glaucoma is a rapidly emerging cause of secondary ocular hypertension caused by trametesterol-induced decreased trabecular outflow. An unnoticed, sustained elevation in pressure can cause irreparable damage to the optic nerve, resulting in visual impairment. Clinical literature has underscored that this condition can be mostly avoided by early diagnosis, rational use of steroids, and timely pressure-reducing interventions99. Improved screening awareness and communication among field specialists are needed as preventive interventions in the current context, given the high rate of corticosteroid prescribing across a broad range of medical specialists.
Secondary glaucomas
Secondary glaucomas are caused by underlying ocular or systemic pathology such as inflammation, ischemia, trauma, neovascularization, or early surgery and can show a more progressive and unfavorable prognosis than the primary disease. Modern knowledge outlines a variety of pathogenic processes that need to be managed by mechanisms and are a consideration in surgical interventions in the initial phases to avoid irreparable optic neuropathy100. The conditions represent instances that require personalized treatment approaches rather than standard treatment algorithms.
Late diagnosis and disease awareness
After the development of extensive and permanent damage to the optic nerve, late presentation is one of the biggest impediments to an effective response to glaucoma. Epidemiologic studies across the globe continue to show high estimates of the unsuspected and persistent obstacles to early diagnosis, especially in disadvantaged resource settings101,102. Enhancing early diagnosis should thus involve community-based screening, incorporating screening into primary care, and increasing the use of tele-ophthalmology and digital imaging technologies, all of which are among the most successful measures for preventing glaucoma-related blindness.
Vulnerabilities: Disaster prevention and health care
The imbalance in access to specialists, coverage of treatment, testing facilities, and follow-up care significantly affects the outcome of glaucoma in the world. The extended burden of health and economics of glaucoma indicates the necessity of equal healthcare provision and sustainability of the treatment paradigm101. Late diagnosis, interruption of treatment, and presentation of diseases at an advanced stage are common characteristics of underserved populations, which underscore the role of health-system strengthening, task-sharing, and the expansion of telemedicine. The research investigates the influence of treatment adherence and outcomes on long-term continuity. The nonadherence to medication is a significant predictor of structural and functional progression due to the fact that glaucoma is a lifelong condition. Longitudinal analysis indicates that a reduction in visual field is directly linked to poorer compliance103. Sustainable treatment is further complicated by behavioral, educational, and socioeconomic barriers, underscoring the need to focus on patient education, simplified regimens, and adherence-support interventions104. New methods like sustained-release drug delivery and prior procedures could help decrease daily usage of topical drugs and enhance long-term disease control.
Burden and cost-effectiveness in economics
The long-term development of glaucoma imposes significant direct medical expenses, indirect productivity losses, and caregiver burden, and visual impairment makes a significant contribution to the economy of the nation105. Glaucoma is also a concern in global burden measurements, prompting the need to address it with effective prevention, early detection, and long-term management strategies that are economically viable101. The future of glaucoma policy, program planning, and equitable provision of vision care, therefore, lies in balancing these two (clinical effectiveness and financial sustainability).
Synthesis of evidence and clinical implications
Glaucoma remains one of the leading causes of irreversible blindness worldwide and is characterized by progressive RGC degeneration, ONH damage, and corresponding visual field loss. Contemporary epidemiologic and clinical evidence underscores the substantial and growing global burden of disease, driven by population aging, improved detection, and persistent barriers to early diagnosis and sustained treatment1,2,3,4,5,81,85. The present review integrates current knowledge across risk factors, pathophysiology, diagnostics, medical and laser therapy, surgical innovation, neuroprotection, and precision-based care, illustrating the transition of glaucoma management from a purely intraocular-pressure (IOP)–centric paradigm toward a multidimensional neurodegenerative disease framework88. The evidence summarized in this review supports a staged, risk-based model of glaucoma care. Established management remains centered on IOP reduction because lowering pressure is the only intervention consistently proven to delay onset and progression. However, current evidence also shows that glaucoma is a multifactorial optic neuropathy in which vascular dysregulation, structural susceptibility, neuroinflammation, mitochondrial dysfunction, genetic background, and adherence behavior modify individual risk. This explains why some patients progress despite apparently controlled IOP and why treatment decisions should be guided by the rate of structural and functional change rather than by isolated pressure readings alone. Current diagnostic innovation has shifted glaucoma care toward earlier detection and objective longitudinal monitoring. OCT and OCTA provide structural and vascular biomarkers that complement visual field testing, while home monitoring, digital perimetry, tele-ophthalmology, and AI-assisted analytics may improve access and the detection of progression. Therapeutic innovation is similarly changing practice. Fixed-dose combinations, ROCK inhibitors, sustained-release delivery, SLT, MIGS, and modern drainage implants provide additional options for reducing IOP and treatment burden. The practical challenge is to match each intervention to the correct patient, disease stage, target IOP, adherence risk, and health-system context.
A central theme emerging from modern research is the multifactorial pathogenesis of glaucomatous damage. Although elevated IOP remains the most important modifiable determinant of onset and progression, vascular dysregulation, mitochondrial dysfunction, oxidative stress, neuroinflammation, excitotoxicity, and genetic susceptibility all contribute to RGC injury and optic neuropathy. These mechanisms help explain why structural and functional deterioration may continue despite apparently adequate IOP control, reinforcing the need for IOP-independent neuroprotective and disease-modifying strategies70,74,75. Advances in risk stratification and early detection have transformed diagnostic capability. Demographic, ocular, systemic, and biomarker-based predictors enable the identification of high-risk individuals and fast progressors, supporting earlier therapeutic escalation and individualized monitoring. High-resolution structural imaging, particularly OCT, permits detection of pre-perimetric neuronal loss, while functional testing refines progression assessment21,26. Emerging technologies such as artificial intelligence–assisted diagnostics and tele-ophthalmology platforms further expand screening capacity and may reduce disparities in underserved populations83,84,94,95. From a therapeutic perspective, topical pharmacologic therapy remains first-line management for most patients. Established drug classes, including prostaglandin analogues, beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors, provide effective IOP reduction and remain foundational to care. More recent agents such as Rho-kinase inhibitors, nitric-oxide–donating therapies, and sustained-release delivery systems reflect ongoing efforts to enhance outflow physiology, reduce treatment burden, and improve adherence. Nevertheless, real-world medication adherence continues to be suboptimal and is strongly associated with disease progression and visual field decline, emphasizing the importance of simplified regimens, patient education, and adherence-support interventions49,91,103,104.
Laser therapies, particularly selective laser trabeculoplasty, have re-emerged as safe and effective primary or adjunctive treatments capable of reducing medication dependence while maintaining IOP control. In parallel, surgical innovation has evolved substantially. While trabeculectomy and glaucoma drainage devices remain essential for advanced or refractory disease, minimally invasive glaucoma surgery offers a better safety profile and enables earlier procedural intervention within the treatment continuum. These developments collectively reflect a shift toward safer, staged, and individualized surgical care.
Beyond pressure reduction, expanding research into neuroprotection, regeneration, and gene-based therapy signals a paradigm shift toward true disease modification. Experimental and translational studies highlight mitochondrial stabilization, oxidative stress reduction, neurotrophin signaling, stem cell–mediated repair, axonal regeneration, and gene therapy as promising avenues, although consistent long-term clinical efficacy remains to be established. The integration of such strategies with durable IOP control may ultimately redefine long-term visual preservation.
Equally important is the emergence of precision medicine and population-specific care. Genetic profiling, imaging biomarkers, artificial intelligence prediction models, and individualized target-IOP determination enable more accurate risk prediction and tailored therapy. Clinical decision-making increasingly incorporates adherence likelihood, comorbidity burden, life expectancy, and quality-of-life considerations, particularly in elderly populations90,93. Pediatric glaucoma, pregnancy-associated disease, steroid-induced glaucoma, and diverse secondary glaucomas each require specialized management strategies reflecting unique developmental, physiologic, or pathogenic mechanisms96,97,98,99,100.
Despite scientific progress, persistent systemic challenges continue to limit outcomes. Late diagnosis remains common globally, with many individuals presenting after irreversible optic nerve damage has occurred102. Disparities in access to care, affordability of treatment, and continuity of follow-up contribute to unequal disease burden and poorer visual outcomes in underserved populations92,101. The chronic economic impact of glaucoma-related visual impairment further underscores the importance of cost-effective prevention and long-term management strategies 101,105. Collectively, these findings highlight that a meaningful reduction in glaucoma blindness will require not only biomedical innovation but also health-system strengthening and equitable care delivery. Future glaucoma management will likely depend on combining durable IOP control with validated biomarkers and disease-modifying strategies. Neuroprotection, regeneration, and gene therapy are promising but remain investigational. Their eventual value will depend on whether they can preserve retinal ganglion cell structure and visual function beyond the benefit achieved by pressure-lowering alone. Therefore, the central clinical message of this review is that modern glaucoma care should be earlier, more individualized, evidence-based, and accessible, with a clear separation among interventions that are established, emerging, or remain future translational goals.
Access restricted. Please log in or start a trial to view this content.
Glaucoma management is evolving from a pressure-focused model toward an integrated strategy that combines early diagnosis, multimodal imaging, functional testing, risk stratification, sustained IOP control, laser and surgical innovation, and personalized long-term care. IOP reduction remains the foundation of treatment, but modern management increasingly recognizes that vascular, inflammatory, metabolic, biomechanical, genetic, and social determinants influence disease progression and treatment success. Current innovatio...
Access restricted. Please log in or start a trial to view this content.
The authors declare no financial conflicts of interest.
Access restricted. Please log in or start a trial to view this content.